Eli Lilly and Company (LLY)vsSera Prognostics Inc (SERA)
LLY
Eli Lilly and Company
$1,188.46
+2.70%
HEALTHCARE · Cap: $1.03T
SERA
Sera Prognostics Inc
$2.07
+0.98%
HEALTHCARE · Cap: $78.90M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 113808477% more annual revenue ($79.67B vs $70,000). LLY leads profitability with a 33.5% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
SERA
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
-73.8%
Fair Value
$1.49
Current Price
$2.07
$0.58 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Reasonable price relative to book value
Revenue surging 76.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : SERA
The strongest argument for SERA centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 76.5% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : SERA
The primary concerns for SERA are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while SERA is a hypergrowth play — different risk/reward profiles.
SERA carries more volatility with a beta of 1.06 — expect wider price swings.
SERA is growing revenue faster at 76.5% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 35/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Sera Prognostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sera Prognostics Inc. is a pioneering force in maternal-fetal health, focusing on cutting-edge diagnostic solutions designed to enhance pregnancy outcomes. Its flagship product, the PreTRM test, harnesses a unique biomarker platform to accurately evaluate the risk of preterm birth, enabling healthcare providers to implement timely and impactful interventions. With a steadfast commitment to advancing prenatal diagnostics and addressing pivotal health challenges, Sera is strategically positioned for significant growth within the maternal health sector, offering investors compelling opportunities for long-term value creation.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?